Medacta Group SA · SIX:MOVE
Medacta Group SA — FY2021 Earnings Presentation
14 slides from Medacta Group SA's earnings presentation, Jan 20, 2022
Slide 1: FY 2021 Preliminary Unaudited Top-Line Figures
FY 2021 PRELIMINARY UNAUDITED TOP-LINE FIGURES 20 January 2022
Slide 2: Disclaimer
DISCLAIMER This presentation (the "Presentation") has been prepared by Medacta Group SA ("Medacta" and together with its subsidiaries, "we", "us" or the "Group"). The information contained in the Presentation does not purport to be comprehensive. Please refer to the financial reports available on ou
Slide 3: Presenters: Francesco Siccardi and Corrado Farsetta
FRANCESCO SICCARDI CORRADO FARSETTA Chief Executive Officer Chief Financial Officer FY 2021 Preliminary Unaudited Top-Line Figures
Slide 4: Highlights
HIGHLIGHTS FY 2021 Revenue1 Revenue Growth vs FY20 Euro 363.1 million 21.4% at constant currency 20.0% reported Positive revenue contribution from all business lines Significant carry-over and customer acquisition, in and geographies addition to normalization of surgical activities, which were limit
Slide 5: Deployment of the NextAR AR Surgical Platform
DEPLOYMENT OF THE NEXTAR™ AR SURGICAL PLATFORM NextAR, our Augmented Reality Surgical Platform, empowers the surgeon’s vision with real-time surgical guidance superimposed onto the operative field to make data-driven decision-making All NextAR Platform applications for knee, shoulder and spine s
Slide 6: Innovation and Product Development
INNOVATION AND PRODUCT DEVELOPMENT Hip – Further enhancement of the AMIS® (Bikini) technique – Expansion of revision systems – As innovative technologies, personalized solutions with 3D preoperative planning and intraoperative verification (MyHip® Planner and MyHip® Verifier) Knee – Continuous f
Slide 7: Marketing and Medical Education Programs
MARKETING AND MEDICAL EDUCATION PROGRAMS Medical Educations back to normal level with significant increase compared to 2019 Decentralized marketing and educational activities proved to be very effective at engaging surgeons and supporting customer acquisition Further strengthening of the M.O.R
Slide 8: Revenue Trend by Semester
REVENUE TREND BY SEMESTER (€m) 21.4% 20.0% 35.4% 10.1% In 2H 2021 elective surgeries were limited by the resurgence of Covid-19 The 2H 2020 comparative period already benefited from previous pent-up demand in certain geographies Notes: U stands for Unaudited figures 8
Slide 9: FY Revenue Bridge by Product Line
FY REVENUE1 BRIDGE BY PRODUCT LINE (€m) 17.8% 24.8% 35.4% 20.4% 21.4% 20.0% (€m) 19.0; 33.8; 5% 9% 179.3; 131.1; 50% 36% 2 Hip Knee Extremities Spine Hip: growth driven by the AMIS® strategy supported by the roll-out of new products Knee: good momentum generated by Kinematic Alignment, Efficienc
Slide 10: FY Revenue Bridge by Geographic Area
FY REVENUE1 BRIDGE BY GEOGRAPHIC AREA (€m) 21.2% 21.9% 17.5% 50.3% 21.4% 20.0% (€m) 12.6; 4% 84.9; 23% 156.4; 43% 109.2; 30% Europe NA APAC ROW Europe: solid growth across all countries despite Covid-19 restrictions in Q1 and Q4 North America: customer acquisition, salesforce expansion and incre
Slide 11: Thank you to all our Employees, Customers and Suppliers
A great thank you to all our Employees for their commitment, resilience, and performance, and to our Customers and Suppliers for their collaboration and support in this challenging time 11
Slide 12: Q&A
Q&A FY 2021 Preliminary Unaudited Top-Line Figures
Slide 13: Thank you for your attention
Thank you for your attention Adedacta 44.0.R.E.
Slide 14: Adedacta
Adedacta International Adedacta 44.0.R.E.